170 related articles for article (PubMed ID: 1327071)
21. Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas.
Cassarino MF; Sesta A; Pagliardini L; Losa M; Lasio G; Cavagnini F; Pecori Giraldi F
Endocrine; 2017 Mar; 55(3):853-860. PubMed ID: 27220856
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
Loli P; Boccardi E; Branca V; Bramerio M; Barberis M; Losa M; Terreni MT; Lodrini S; Pollo B; Vignati F
Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
[TBL] [Abstract][Full Text] [Related]
23. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
24. Proopiomelanocortin processing and prohormone convertase 1 level in dogs with pituitary corticotroph tumors.
Benchekroun G; de Fornel-Thibaud P; Rosenberg D
Domest Anim Endocrinol; 2018 Jan; 62():83-87. PubMed ID: 29145000
[TBL] [Abstract][Full Text] [Related]
25. [Pathology and pathogenesis of pituitary corticotroph adenoma].
Trouillas J
Neurochirurgie; 2002 May; 48(2-3 Pt 2):149-62. PubMed ID: 12058122
[TBL] [Abstract][Full Text] [Related]
26. ACTH, beta-LPH and beta-endorphin in pituitary adenomas of the patients with Cushing's disease: activation of beta-LPH conversion to beta-endorphin.
Suda T; Abe Y; Demura H; Demura R; Shizume K; Tamahashi N; Sasano N
J Clin Endocrinol Metab; 1979 Sep; 49(3):475-7. PubMed ID: 224076
[TBL] [Abstract][Full Text] [Related]
27. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
28. Ectopic pro-opiomelanocortin syndrome.
Beuschlein F; Hammer GD
Endocrinol Metab Clin North Am; 2002 Mar; 31(1):191-234. PubMed ID: 12055989
[TBL] [Abstract][Full Text] [Related]
29. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
30. Significant gene expression of insulin-like growth factor II and proliferating cell nuclear antigen in a rapidly growing recurrent pituitary acth-secreting adenoma.
Hashimoto K; Nagano I; Asaba K; Inoue M; Nishioka T; Takao T; Nakajo T; Mori T; Kurisaka M; Otsuka F
Horm Res; 2000; 54(4):198-202. PubMed ID: 11416238
[TBL] [Abstract][Full Text] [Related]
31. Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease.
Granger N; de Fornel P; Devauchelle P; Segond S; Delisle F; Rosenberg D
J Vet Intern Med; 2005; 19(1):23-8. PubMed ID: 15715043
[TBL] [Abstract][Full Text] [Related]
32. Aberrant production and regulation of proopiomelanocortin-derived peptides in ectopic Cushing's syndrome.
Roth KA; Newell DC; Dorin RI; Eberwine JH; Hoffman AR
Horm Metab Res; 1988 Apr; 20(4):225-9. PubMed ID: 2456259
[TBL] [Abstract][Full Text] [Related]
33. AZA-deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors.
Cassarino MF; Sesta A; Pagliardini L; Losa M; Lasio G; Cavagnini F; Pecori Giraldi F
Pituitary; 2014 Oct; 17(5):464-9. PubMed ID: 24085685
[TBL] [Abstract][Full Text] [Related]
34. Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro.
Suda T; Tozawa F; Yamada M; Ushiyama T; Tomori N; Sumitomo T; Nakagami Y; Demura H; Shizume K
J Clin Invest; 1988 Jul; 82(1):110-4. PubMed ID: 2839542
[TBL] [Abstract][Full Text] [Related]
35. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
36. Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.
Wilson MG; Nicholson WE; Holscher MA; Sherrell BJ; Mount CD; Orth DN
Endocrinology; 1982 Mar; 110(3):941-54. PubMed ID: 6276164
[TBL] [Abstract][Full Text] [Related]
37. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
38. In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas.
Stefaneanu L; Kovacs K; Horvath E; Lloyd RV
Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):107-13. PubMed ID: 1651583
[TBL] [Abstract][Full Text] [Related]
39. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations.
Peterson ME; Orth DN; Halmi NS; Zielinski AC; Davis DR; Chavez FT; Drucker WD
Endocrinology; 1986 Aug; 119(2):720-30. PubMed ID: 3015556
[TBL] [Abstract][Full Text] [Related]
40. High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma.
Comtois R; Beauregard H; Hardy J; Robert F; Somma M
Clin Endocrinol (Oxf); 1993 Jun; 38(6):601-7. PubMed ID: 8392915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
